In patient-centered outcomes research, it is vital to assess the heterogeneity of treatment effects (HTE) when making health care decisions for an individual patient or a group of patients. Nevertheless, it remains challenging to evaluate HTE based on information collected from clinical studies that are often designed and conducted to evaluate the efficacy of a treatment for the overall population. The Bayesian framework offers a principled and flexible approach to estimate and compare treatment effects across subgroups of patients defined by their characteristics. In this paper, we describe the package beanz that facilitates the conduct of Bayesian analysis of HTE by allowing users to explore a wide range of Bayesian HTE analysis models and produce posterior inferences about HTE. The package beanz also provides a web-based graphical user interface (GUI) for users to conduct the Bayesian analysis of HTE in an interactive and user-friendly manner. With the GUI feature, beanz can also be used by analysts not familiar with the R environment. We demonstrate beanz using data from a randomized controlled trial on angiotensin converting enzyme inhibitor for treating congestive heart failure (N = 2569).
Introduction
Clinical trials typically evaluate the efficacy of a medical intervention based on its overall treatment effect, the average benefit or harm the enrolled patients will achieve. However, individuals respond to medical interventions in different ways. Even for a treatment that is effective on average, some individuals may derive substantial benefit; some little benefit, others could actually be harmed. Thus, understanding this heterogeneity of treatment effect (HTE) is critical in evaluating how well a treatment can be expected to work for an individual patient. Such understanding is especially important in patient-centered outcomes research (PCOR) that aims to help patients and stakeholders make informed personalized health care decisions (Varadhan, Segal, Boyd, Wu, and Weiss 2013) .
Although the importance of understanding HTE is obvious, reliable identification of HTE is challenging. Ideally, we would like to be able to estimate individual treatment effects (ITE). However, ITE estimation is not feasible because it's impossible to observe the outcomes of both the treatment and control for the same individual. This is the fundamental problem of causal inference (Holland 1986) . Consequently, subgroup analysis is commonly used to evaluate HTE, but it is challenging due to the need to specify the groups and control for multiplicity in a low-information context.
The Bayesian approach provides a principled way to formulate consideration of the differences in treatment effect across patient characteristics. The approach includes a prior distribution that allows expression of optimism, skepticism or agnosticism concerning the differences in treatment effect. The Bayesian approach also allows a great deal of flexibility in making inferences on a variety of questions (e.g., what is the probability that women derive more benefit from the treatment than men?). A frequentist approach, on the other hand, would ask: "what is the probability of observing a difference in treatment effect between men and women, if in truth there were no difference?" This way of framing the question implies a premature dichotomization: the treatment effect is either the same in men and women or it is not, based on arbitrary conventions (e.g., the significance level is 0.05). While the Bayesian approach is principled and flexible, there are several challenges in conducting Bayesian HTE analysis, including the need to specify prior distributions, little guidance, and the lack of easy-to-use software to implement the HTE models.
There are several software packages on the Comprehensive R Archive Network (CRAN), most of which implement frequentist methods, for subgroup analysis. The package Quint (Dusseldorp, Doove, and Mechelen 2015) applies a tree-based clustering method for inducing subgroups that are involved in qualitative treatment-subgroup interactions. The pacakge subgroup on CRAN (Schou and Marschner 2014) considers order statistics-based measures to evaluate the magnitude and the nature of the variation in treatment effects and provides non-inferential visual aids. The package FINDIt (Egami, Ratkovic, and Imai 2015) applies machine learning methods to identify subsets of the population who benefit or are harmed by a treatment and to select the most or least efficacious treatment from many alternative treatments. The package DSBayes (Varadhan and Yao 2014) implements the Bayesian Dixon and Simon model (Dixon and Simon 1991) for subgroup analysis. To the best of our knowledge, there is no statistical software package for comprehensive Bayesian HTE analysis, let alone one with a graphical user interface (GUI).
To this end, we describe an R package beanz that facilitates the conduct of Bayesian HTE analysis. The package gives users the ability to explore a wide range of Bayesian HTE analysis models and obtain posterior inferences related to HTE. Specifically, we develop a web-based GUI for beanz that allows users to apply functions in beanz in an interactive and user-friendly manner. With the GUI feature, beanz can also be used by analysts not familiar with the R environment.
In this paper, we use the data from the SOLVD trial (Investigators et al. 1991) for the demonstration of beanz. SOLVD was a randomized, double-blind, placebo-controlled study evaluating the efficacy of the drug Enalapril compared to placebo on mortality and hospitalization in patients with congestive heart failure (CHF). From 1986 to 1989, a total of 2569 patients with CHF and ejection fraction ≤ 0.35 were enrolled and randomly assigned to the Enalapril arm or the placebo arm in a 1:1 randomization ratio. At the end of the study, 735 patients had died or were hospitalized in the placebo group as compared with 613 in the Enalapril group. The overall treatment effect on mortality was statistically significant with log-rank test p-value < 0.0001. The SOLVD protocol pre-specified examination of subgroup effects for clinically important baseline factors. For the current demonstration we focus on baseline covariates sodium level, usage of vasodilators other than angiotensin-converting-enzyme inhibitors, and ejection fraction.
The reminder of the paper is organized as follows. In Section 2, we introduce the Bayesian HTE analysis models implemented in beanz. In Section 3, we demonstrate the beanz package, used in the R interactive mode, with a comprehensive example using data from SOLVD. In Section 4, we describe the details of the GUI of beanz, including its architecture and user manual. We revisit the SOLVD example to illustrate the GUI of beanz in Section 5. Section 6 is devoted to discussion.
Probability models 2.1. Notation
Consider a randomized two-arm clinical trial (Z = 0, 1). For patient i, let Y i denote the response and Z i denote treatment arm assignment. For subgroup analysis, assume there are P baseline covariates of interest, X 1 , X 2 , . . . , X P , that are binary, ordinal with numerical values, or nominal. If a covariate is ordinal with character labels, then we assume the covariate can be re-coded with numerical values. For j = 1, . . . , P , assume X j ∈ {x j,1 , . . . , x j,n j } with n j ≥ 2. If X j is binary or ordinal with numerical values, x j,k (k = 1, . . . , n j ) denotes the value of the kth level of X j . If X j is a nominal variable, x j,k denotes the vector of dummy variables with dimension n j − 1 that corresponds to the kth level of X j . For example, if X j is patients' race with three levels: "white", "black" and "other", we may have x j,1 = (0, 0) for "white", x j,2 = (0, 1) for "black" and x j,1 = (1, 0) for "other".
Let Ω = (X 1 , . . . , X P ) : X j ∈ {x j,1 , . . . , x j,n j } for j = 1, . . . , P denote the collection of subgroups defined by X 1 , . . . , X P . Let G i ∈ Ω denote the subgroup for patient i, and X g = (X g,1 , . . . , X g,P ) be the covariates for subgroup G = g. Let θ g denote the treatment effect in subgroup G = g, and let θ g be the estimated θ in subgroup G = g with σ 2 g the estimated variance associated with θ g . Note, θ g may be measured on different scales. For example, if response is continuous, we may define
If response is binary, we may define θ g = P (Y = 1|Z = 1, G = g) P (Y = 0|Z = 1, G = g) P (Y = 0|Z = 0, G = g) P (Y = 1|Z = 0, G = g) .
beanz: Bayesian Analysis of Heterogeneous Treatment Effect
If response is time-to-event, we may define
where λ z,g is the hazard rate of arm Z = z in subgroup G = g.
Bayesian models
We consider the subgroup modeling strategy and selection of Bayesian hierarchical models suggested by Jones, Ohlssen, Neuenschwander, Racine, and Branson (2011) . First, assume that the estimated treatment effect θ g in subgroup G = g approximately follows a normal distribution,
We then assign an informative prior to σ 2
where ∆ 1 and ∆ 2 are parameters specified by the users. This informative prior is "centered" at the point estimate of the variance σ 2 g corresponding to θ g and allows to take into account the uncertainty in σ 2 g by parameters ∆ 1 and ∆ 2 . Note that in Jones et al. (2011) , σ 2 g was assumed known, which is equivalent to setting ∆ 1 and ∆ 2 to be 0 and assume θ g |θ g ∼ N (θ g , σ 2 g ). This is also the default option in beanz.
Next, we consider a set of models together with the priors for parameters in θ g . These models include:
No subgroup effect model:
where B is large in relation to the magnitude of the treatment effect size so that the prior for µ is essentially non-informative.
Note. This model assumes that patients in all the subgroups are exchangeable. That is, all the subgroups are statistically identical with regard to the treatment effect and there is no subgroup effect. Information about treatment effects can be directly combined from all subgroups for inference.
Full stratification model:
Note. The subgroups are fully distinguished from each other with regard to the treatment effect. There is no information about treatment effects shared between any subgroups.
Simple regression model:
Note. When X j is nominal, X g,j and γ j are vectors with dimension n j −1 and 1 is a dimension n j − 1 diagonal matrix. Otherwise, X g,j and γ j are scalars and 1 is scalar 1. Unless specified, the same notation and modeling strategy also apply to the following Simple regression and shrinkage model, Dixon and Simon model and Extended Dixon and Simon model.
The model introduces a first-order, linear regression structure for θ g . This model takes into account the information that the subgroups are formulated based on the set of baseline covariates X 1 , . . . , X p . The coefficients µ and γ j 's are assumed to be exchangeable among subgroups. Information about treatment effects are shared between subgroups with similar baseline covariates through these coefficients.
Basic shrinkage model:
where Half-N denotes the Half-normal distribution with variance C. By definition, when ω ∼ N (0, C), ω = |ω | follows a Half-N (C) distribution.
Note. Here, φ g denotes a random subgroup effect for subgroup G = g and, directly estimated subgroup treatment effects are shrunken towards the overall mean µ. This approach assumes all subgroups are exchangeable with regards to the treatment effect.
Simple regression and shrinkage model:
Note. This model combines basic regression with shrinkage, with a linear regression structure and a random effect term. Direct estimates are shrunken towards the regression surface.
Dixon and Simon model (Dixon and Simon 1991) :
Note. This model assumes that the elements in coefficient γ j 's are exchangeable with each other, which allows information sharing among covariate effects. Similar to the simple regression model, only the first-order interactions are considered.
Extended Dixon and Simon model:
where ξ (k) denotes the set of kth order interaction terms among X 1 , . . . , X P and X ξ (k) ,j denotes the jth element in ξ (k) . The dimension of γ (k) j and 1 is the same as X ξ (k) ,j .
Note. This approach extends the Dixon and Simon model by introducing the higher-order interactions, with the interaction effects exchangeable.
Inference
Treatment effect evaluation and treatment effect comparison among subgroups are based on the posterior distribution p(θ g | θ g , σ 2 g , ∆ 1 , ∆ 2 ).
The beanz package

Installation
The beanz package is available from CRAN at http://CRAN.R-project.org/package=beanz. To install and load beanz, type the following in R:
The major functions provided in beanz are listed in Table 1 .
Data format
There are two types of data structures that beanz recognizes:
• Patient level raw data. Each row should represent a patient with covariates that define the subgroup in which the patient belongs to, treatment indicator and outcome. The outcome can be binary, continuous, or time to event.
• Summary treatment effect data. Each row should represent a subgroup with covariates that define the subgroup, estimated treatment effect in the subgroup and variance for the estimation.
The package beanz provides dataset solvd.sub from the SOLVD trial as an example of Patient level raw data. For continuous and binary response data, r.get.subgrp.raw calls glm with model
where g(·) is the identity or logit link function. For time to event data, beanz calls the coxph function in package survival (Therneau 2015) with proportional hazard model
The model parameter estimation θ g and the associated variance σ 2 g are further used in the Bayesian HTE analysis.
R> subgrp.effect <-r.get.subgrp.raw(solvd.sub, var.resp = "y", + var.trt = "trt", + var.cov = c("lvef", "sodium", "any.vasodilator.use"), + var.censor = "censor", resptype = "survival");
R> print(subgrp.effect); We consider the Simple regression model in the following example:
R> var.cov <-c("lvef", "sodium", "any.vasodilator.use"); R> var.estvar <-c("Estimate", "Variance"); R> rst.sr <-call.stan(mdls = "sr", dat.sub = subgrp.effect, + var.estvar = var.estvar, var.cov = var.cov, + lst.par.pri = list(vtau = 1000, vgamma = 1000, vrange = c(0,0)), + chains = 1, iter = 4000, warmup = 2000, thin = 2, seed = 1000);
The function r.summary.stan creates a data frame with the summary of the posterior subgroup treatment effects. The summary statistics include the posterior mean, SD, 2.5%, 25%, 50%, 75%, 97.5% quantiles of the treatment effect in each selected subgroup and the posterior probability that the subgroup treatment effect is less than a given cut-off value, which can be specified by parameter cut.
The following example shows the posterior subgroup treatment effect summary table for the Simple regression model.
R> tbl.sub <-r.summary.stan(rst.sr, digits = 2, cut = 0); R> print(tbl.sub[,-1]);
Mean SD 2.5% 25% Median 75% 97.5% Prob<0 Subgroup 1 "-0.4" "0.1" "-0.59" "-0.47" "-0.4" "-0.34" "-0.23" "1" Subgroup 2 "-0.38" "0.08" "-0.55" "-0.44" "-0.38" "-0.32" "-0.22" "1" Subgroup 3 "-0.49" "0.13" "-0.72" "-0.58" "-0.49" "-0.4" "-0.24" "1" Subgroup 4 "-0.47" "0.13" "-0.72" "-0.55" "-0.46" "-0.38" "-0.23" "1" Subgroup 5 "-0.06" "0.13" "-0.32" "-0.15" "-0.06" "0.02" "0.17" "0.69" Subgroup 6 "-0.04" "0.11" "-0.27" "-0.12" "-0.04" "0.04" "0.18" "0.64" Subgroup 7 "-0.15" "0.15" "-0.44" "-0.26" "-0.15" "-0.04" "0.15" "0.84" Subgroup 8 "-0.13" "0.15" "-0.43" "-0.23" "-0.12" "-0.03" "0.15" "0.81"
The package beanz also provides functions r.plot.stan and r.forest.stan to present the posterior densities and forest plots (Lewis and Clarke 2001) , respectively, for the posterior subgroup treatment effects (Figure 1 The beanz package provides functions for treatment effect comparisons between subgroup. The function r.summary.comp creates a data frame with the summary of the posterior subgroup treatment effect differences between subgroups. The parameter sel.grps allows to select specific subgroups for the comparison.
R> tbl.sub <-r.summary.comp(rst.sr, sel.grps = 1:3, + digits = 2, cut = 0); R> print(tbl.sub[,-1]); Mean SD 2.5% 25% Median 75% 97.5% Prob<0 Subgroup 2-1 "0.02" "0.13" "-0.23" "-0.07" "0.02" "0.1" "0.25" "0.44" Subgroup 3-1 "-0.1" "0.15" "-0.42" "-0.2" "-0.09" "0.01" "0.2" "0.74" Subgroup 3-2 "-0.11" "0.15" "-0.39" "-0.22" "-0.11" "-0.01" "0.19" "0.77"
The functions r.plot.comp and r.forest.comp present the posterior densities and forest plots, respectively, for the posterior subgroup treatment effect differences (Figure 2 ). R> r.plot.comp(rst.sr, sel.grps = 1:3); R> r.forest.comp(rst.sr, sel.grps = 1:3);
Model selection
We consider the Basic shrinkage model and compare its deviance information criterion (DIC) with the Simple regression model. 
Gail-Simon qualitative interaction test
Qualitative interaction is a type of treatment effect heterogeneity, where one or more of the subgroups have treatment effect in the opposite direction relative to the overall treatment effect. It is critically important to detect such interactions, if they are present. The package beanz provides the frequentist Gail-Simon qualitative interaction test (Gail and Simon 1985) for examining qualitative interactions by function r.gailsimon. The Gail-Simon test examines the null hypothesis that all the subgroup treatment contrasts lie within the positive orthant O + = {G g : θ g ≥ d} or in the negative orthant, O − = {G g : θ g ≤ −d}, where d ≥ 0 denotes the threshold for clinically meaningful qualitative interaction.
The Gail-Simon test is to reject the null of no qualitative interaction if both of the following conditions are met:
The critical value c is calculated such that when Ω ⊂ O − or Ω ⊂ O + , the probability that both Equations 12 and 13 hold is no greater than the significance level α.
R> gs.pval <-r.gailsimon(subgrp.effect$Estimate, + sqrt(subgrp.effect$Variance)); R> print(gs.pval);
[1] 0.9191656
The Gail-Simon test p-value is 0.9192, which shows that there is no significant qualitative interactions in the SOLVD data.
The beanz GUI
Overall architecture
The beanz GUI is web-based and developed in R using the Shiny(RStudio, Inc 2013) web application framework. Figure 3 shows the architecture of the beanz GUI.
The GUI can be accessed within R using the function run.beanz:
R> run.beanz()
The function run.beanz calls runApp function in package shiny (Chang, Cheng, Allaire, Xie, and McPherson 2016) . The function runApp normally does not return and one may interrupt R to stop the GUI application (e.g., by pressing Ctrl+C).
Alternatively, an online version of the beanz GUI is available at https://olssol.shinyapps. io/beanz/. 
Tabpanel description
The main tabpanels that can be accessed through the menubar in beanz GUI include Start, Upload Data, Subgroup Specification, Configuration, Bayesian Analysis, Toolbox and Report. The details of each panel are given as follows:
Start Panel:
The Start panel serves as an introduction page for the software. The sections on this panel include:
• What does beanz do? Presents the background introduction to beanz and the basic steps of using the software.
• What does beanz need? Explains the different formats of the datafile that beanz accepts.
• What does beanz provide? Introduces the product generated from beanz analysis.
Upload Data Panel:
The Upload Data panel provides interface for users to upload the data to be analyzed. The sections and items within each section on this panel include:
• Upload Data
Choose File
Clicking the Browse... button will load local data files in csv or plain text format.
Data Format
Summary treatment effect data or Patient level raw data.
Separator
Field separating character.
Quote
Quoting character.
Other
There are two additional options: Header. Checkbox indicating if the first line of the file are the names of the columns. Show Data. Checkbox indicating whether to present the uploaded data in the Review Data section on this panel.
• Try An Example Clicking the Try it button will load the example SOLVD Patient level raw data dataset. Details of the example dataset is also given in this section.
• Review Data Presents the uploaded dataset in a table view.
Subgroup Specification Panel:
The Subgroup Specification panel is designed to identify the columns from the uploaded dataset for formulating subgroups. This panel is only available after a data file has been successfully uploaded. The sections and items within each section on this panel include:
• Select Variables
Treatment Effect Estimates
Dropdown list for specifying the column for treatment effect estimation. Only available for Summary treatment effect data.
Treatment Effect Variance
Dropdown list for specifying the column for the variance associated with the treatment effect estimation. Only available for Summary treatment effect data.
Treatment
Dropdown list for specifying the column for treatment. Only available for Patient level raw data.
Response
Dropdown list for specifying the column for response. Only available for Patient level raw data.
Censoring
Dropdown list for specifying the column for censoring. Only available for Patient level raw data with response that is Time to event with treatment effect measured by log hazard ratio. 
Get Subgroups
Button for generating subgroups based on the column specifications. A specification validation check will be first conducted. If there are errors in the specifications, error messages will be shown in this section.
• Subgroups Provides a table view of the subgroups. Each row represents a subgroup and the columns include covariates, treatment effect estimation and the variance associated with the treatment effect estimation.
Configuration Panel:
The Configuration panel contains options for Bayesian model priors, MCMC sampling and results presentation. The sections and items within each section on this panel include:
• Statistical Models and Priors Checkboxes for selecting the Bayesian models to include in the analysis. Note the No subgroup effect model is always included.
For each model, sliders are provided for specifying the parameters in the priors. See Section 2 for details of the priors.
• MCMC Parameters
Number of iterations
STAN parameter specifying how many iterations including burn-in for posterior sampling.
Number of burn-in STAN parameter specifying how many burn-in for posterior sampling.
Number of thinning STAN parameter specifying the period for saving posterior samples.
Random seed STAN parameter for random number generation.
Algorithm STAN parameter for Bayesian sampling algorithms. See rstan for details.
Uncertainty of log variance
Slider for specifying parameters ∆ 1 and ∆ 2 .
• Display Parameters
Cut off for treatment effects
The subgroup treatment effect result tables will present the probability that the subgroup effect is less than this cut off value.
Cut off for comparison
The treatment effect comparison between subgroups result tables will present the probability that the subgroup treatment effect difference is less than this cut off value.
Digits
Integer indicating the number of decimal places in the result tables.
Maximum subgroups for comparison plots
When the number of subgroups is large, the treatment effect comparison density plots will not be presented. This integer specifies the maximum number of subgroups for the plot to display.
Organize results
Different ways to present the analysis results: 
Select subgroups to display
A table for selecting a subset of subgroups to be included in the result presentation. The selected subgroups are highlighted in the table.
Bayesian Analysis Panel:
The Bayesian Analysis panel allows users to conduct the Bayesian analysis by clicking the Conduct Bayesian Analysis button and presents the analysis results following the display configurations on the Configuration panel. This panel is only available after subgroups have been successfully specified.
The sections and items within each section on this panel include:
• Effect   Table Presents the posterior mean, SD, 2.5%, 25%, 50%, 75%, 97.5% quantiles of the treatment effect in each selected subgroup (see Select subgroups to display) and the posterior probability that the subgroup treatment effect is less than a given cut-off value (see Cut off for treatment effects).
Density
Presents the posterior density plots of the subgroup treatment effects for the selected subgroups.
Forest plot
Presents the posterior forest plots of the subgroup treatment effects for the selected subgroups.
• Comparison Table
Presents the posterior mean, SD, 2.5%, 25%, 50%, 75%, 97.5% quantiles of the treatment effect difference in each pairwise comparison of the selected subgroups and the posterior probability that the subgroup treatment effect difference is less than a given cut-off value (see Cut off for comparison).
Density
Presents the posterior density plots of the treatment effect difference for each pairwise comparison of the selected subgroups.
Forest plot
Presents the posterior forest plots of the treatment effect difference for each pairwise comparison of the selected subgroups.
• STAN Diagnosis DIC Presents the deviance information criterion (DIC).
Output
Presents the outputs from STAN.
Trace plot
Presents trace plots of the posterior samples for evaluating the convergence of the Monte-Carlo sampling chains.
Toolbox Panel:
The Toolbox Panel provides tools that implement frequentist methods for the evaluation of HTE. The sections on this panel include:
• ANOINT By clicking the Conduct Analysis button, beanz conducts frequentist subgroup analysis using the anoint package and presents the outputs generated in R in this section. The details of anoint can be found in Varadhan and Kovalchik (2015) .
This section is only available for Patient level raw data and when subgroups have been successfully formulated.
• Gail-Simon Test for Qualitative Interactions Provides p-value for the Gail-Simon test for qualitative interactions. See Section 3.5 for details.
Clinically meaningful threshold allows user to specify the threshold for defining the positive and negative orthants.
Report Panel:
The Report panel presents a summary of the Bayesian analysis results and provides a link for downloading a final report. This panel is only available after the Bayesian analysis has been successfully conducted. The sections on this panel include:
• Summary Presents a summary result table for the selected subgroups. The table contains columns of covariates, treatment effect posterior mean and SD, and the posterior probability that the treatment effect is smaller than a cut-off value. The results are generated by the Bayesian model that is most favorable based on DIC with the given set of priors.
• Download the analysis report The final report can be downloaded by clicking the Download button. The available document formats for the report include PDF, HTML and Word.
Demonstration of beanz GUI
We demonstrate the beanz GUI using the SOLVD clinical trial data in this section. A Youtube video of this demonstration can be found at https://youtu.be/g4JfQ2H7LIc.
Step 1. We first upload the patient-level SOLVD data file to beanz from the Upload Data panel (Figure 4 ). One can also load the data from beanz by clicking the Try it button.
Step 2. Next, on the Subgroup Specification panel we first select the Type of response to be time-to-event. We then specify the columns for Treatment, Response and Censoring and then include the baseline covariates sodium, vasodilator and LVEF indicators. By clicking the Get Subgroups button, beanz checks the validation of the subgroup specification, estimates the treatment effect that is measured by log hazard ratio for each subgroup and reports them in the Subgroups section on this panel ( Figure 5 ).
We can see that there are a total of 8 subgroups. The subgroup with ejection fraction > 29%, sodium > 141 and no vasodilator (subgroup 7) shows the least Enalapril drug effect with θ 7 = 0.15.
Step 3. After the subgroups are formulated, on the Configuration panel, for this demonstration, we select the Simple regression and the Basic shrinkage models with their default priors (B = 1000, C = 100) for the Bayesian analysis ( Figure 6 ). We use the default MCMC parameters: 4000 iterations, 2000 burn-in and 2 thinning. We set the random seed for STAN to be 1000 and use the default sampling method NUTS. Lastly, we set the parameters ∆ 1 = ∆ 2 = 0 for σ 2 g . For reporting results, we set the cut-off value for subgroup treatment effects to be 0 to report the posterior probability that the log hazard ratio is smaller than 0. We use the default value 0 for the cut-off value for subgroup treatment effect differences. We also set the format of the result tables with default value 3 digits. We choose the "By model" option that organizes results with each column presenting a model. Lastly, we choose the "Display no subgroup effect outcome" option to present the results from No subgroup effect model as a reference (Figure 7) .
Step 4. Next, we move to the Bayesian Analysis panel. A warning is given on the panel to caution the users of the importance of model and prior assumptions. A progress bar will appear indicating the progress of STAN analysis after clicking the Conduct Bayesian Analysis button. When the analysis is completed, the results will be presented according to the configuration options from the Configuration panel.
Figures 8-10 present the subgroup treatment effect table, density plot and forest plot for the Basic shrinkage model with the given priors. We observe that the overall Enalapril effect is significant if we assume there is no subgroup effect. With the Basic shrinkage model, the subgroups with ejection fraction ≤ 29% (subgroups 1-4) are all showing strong evidence for the Enalapril effect. Nonetheless, for all the subgroups with ejection fraction > 29% (subgroups 5-8), there is not sufficient evidence to show that the Enalapril is superior to the placebo.
As a comparison, Figure 11 presents the subgroup treatment effect forest plot for Simple regression model. The results from the Simple regression model are similar to the Basic shrinkage model: significant Enalapril effects are only observed in subgroups 1-4.
Next, for patients with sodium ≤ 141 and no vasodilator, we evaluate the treatment effect difference between the subgroups with ejection fraction ≤ 29% (subgroup 1) and > 29% (subgroup 5). Figure 12 shows how to select the subgroups of interest in the Display parameter section on the Configuration panel. Figure 13 presents the comparison forest plot based on the Basic shrinkage model. We observe evidence that suggests there may exist treatment by ejection fraction interaction: the Enalapril drug seems to be more effective for the patients with ejection fraction ≤ 29%, sodium ≤ 141 and no vasodilator, compared to the patients with ejection fraction > 29%, sodium ≤ 141 and no vasodilator, but the difference is not significant.
Step 5. At the end, on the Report panel, a summary result table is provided based on the model that is most favorable according to DIC. The analysis report can be downloaded as a PDF, HTML, or Word document (Figure 14) . The report contains sections for Data Summary, Subgroup Definition, Analysis Results for each selected model, and the Summary results. Figure 15 shows the contents page of an example report. 
Discussion
In this era of precision medicine, it is not sufficient to evaluate the efficacy of a medical intervention based only on its average treatment effect. It is critical to be able to better understand the nature and sources of heterogeneity in treatment effect in order to help patients and stakeholders make informed health care decisions.
The Bayesian approach offers a principled and flexible way for evaluating the differences in treatment effect across patient characteristics. It is a formal approach to combine evidence from the study at hand with external information or subjective beliefs to answer decisiondriven questions from the varied perspectives of different stakeholders.
A major impediment to the conduct of Bayesian subgroup analysis is the lack of user-friendly software. We attempt to solve this problem by providing, for the first time, an R package software tool with web-based GUI, which makes it easy to carry out Bayesian subgroup analysis. Our software readily facilitates integral aspects of a Bayesian analysis including prior specification, model specification (choosing from a suite of models), control of MCMC simulation settings, visualization of posterior densities, tabular presentation of numerical summaries, and report generation.
We also provide a toolbox for conducting frequentist analysis via fitting regression models with interactions between treatment and baseline covariates, by linking to the R package anoint, which provides an extensive array of subgroup analysis techniques and interaction models. The toolbox also provides a likelihood ratio test for detecting qualitative interactions (Gail and Simon 1985) .
A potential limitation of the models represented in our software is that the subgroup treatment effects are assumed to follow a normal distribution. For certain scenarios such as analysis of rare events, the normal approximation may not be appropriate (Jones et al. 2011) . Nevertheless, maximum likelihood estimates with large information will be approximately normal at least in some scale for most cases. Moreover, the normal approximation allows for relatively straightforward interpretation of the models considered for the mean of θ g . In practice, one can transform for improved normality although such transformation may move from the clinically relevant scale. This is the first release of the software, we plan to include other distributions in subsequent versions of the software.
